These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 28138962)
1. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
2. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target. Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519 [TBL] [Abstract][Full Text] [Related]
3. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124 [TBL] [Abstract][Full Text] [Related]
5. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643 [TBL] [Abstract][Full Text] [Related]
6. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma. Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785 [TBL] [Abstract][Full Text] [Related]
7. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889 [TBL] [Abstract][Full Text] [Related]
8. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
9. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
10. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Dietz KN; Miller PJ; Hollenbach AD Biochemistry; 2009 Dec; 48(49):11786-95. PubMed ID: 19904978 [TBL] [Abstract][Full Text] [Related]
12. The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. Schmitt-Ney M; Camussi G PLoS One; 2015; 10(3):e0121474. PubMed ID: 25806826 [TBL] [Abstract][Full Text] [Related]
13. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Xia SJ; Holder DD; Pawel BR; Zhang C; Barr FG Am J Pathol; 2009 Dec; 175(6):2600-8. PubMed ID: 19893043 [TBL] [Abstract][Full Text] [Related]
14. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Dietz KN; Miller PJ; Iyengar AS; Loupe JM; Hollenbach AD Int J Biochem Cell Biol; 2011 Jun; 43(6):936-45. PubMed ID: 21440083 [TBL] [Abstract][Full Text] [Related]